Fibroblast growth factor 21 is elevated in metabolically unhealthy obesity and affects lipid deposition, adipogenesis, and adipokine secretion of human abdominal subcutaneous adipocytes

• Main Authors: Lucia Berti (Author), Martin Irmler (Author), Marty Zdichavsky (Author), Tobias Meile (Author), Anja Böhm (Author), Norbert Stefan (Author), Andreas Fritsche (Author), Johannes Beckers (Author), Alfred Königsrainer (Author), Hans-Ulrich Häring (Author), Martin Hrabě de Angelis (Author), Harald Staiger (Author)
• Format: Book
• Published: Elsevier, 2015-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Serum concentrations of the hepatokine fibroblast growth factor (FGF) 21 are elevated in obesity, type-2 diabetes, and the metabolic syndrome. We asked whether FGF21 levels differ between subjects with metabolically healthy vs. unhealthy obesity (MHO vs. MUHO), opening the possibility tha...